Don't break up: The Tipline for 1 May 2019
Some believe the era of bipartisanship on Capitol Hill ended a long time ago. But those people clearly forget about the bonding powers of pharmaceutical-related antitrust legislation. The House Judiciary Committee cleared four bills related to competition in the drug industry yesterday with representatives from both sides of the aisle taking turns to praise the legislation. Meanwhile, FTC commissioner Noah Phillips said he is unconvinced that breaking up companies – rather than issuing behavioural remedies – is a better solution to address monopolistic practices in the technology sector.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10